|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 2/01/18 Gala Pharmaceutical Inc. 8-K:5,9 1/10/18 2:24K GlobalOne Filings Inc/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 13K 2: EX-3.1 Certificate of Amendment HTML 7K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
JANUARY 10,
2018
Date of Report (Date of earliest event reported)
GALA PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
| NEVADA | 000-52044 | 42-1771014 |
| (State or other jurisdiction of | (Commission File | (IRS Employer Identification No.) |
| incorporation) | Number) |
| 2780 South Jones Blvd., #3725, Las Vegas, Nevada | 89146 | |
| (Address of principal executive offices) | (Zip Code) | |
(949) 851-9261
Registrant's telephone number, including area code
GALA GLOBAL INC.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 5.02. | DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS |
As of January 19, 2018, the relationship with Joseph Earle, the recently appointed Chief Operation Officer, was ended along with the related consulting agreement. As litigation is possible from this event, any documents or communication sent to or received from Mr. Earle or his attorney are being handled directly by our attorney.
| ITEM 5.03 | AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR. |
Gala Global Inc., effective January 10, 2018 has changed its name to Gala Pharmaceutical, Inc. On or about December 4, 2017, a majority of Gala Global, Inc. shareholders consented to the change which was approved by the Board of Directors the same day. On December 5, 2018 the Articles of Incorporation were amended to reflect the name change.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
| Exhibit No. | Description |
| 3.1 | Certificate of Amendment to Certificate of Incorporation |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Gala Pharmaceutical Inc. | ||
| Date: February 1, 2018 | By: | /s/ Maqsood Rehman |
| Maqsood Rehman | ||
| Title: | Chief Executive Officer | |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/5/18 | None on these Dates | |||
| Filed on: | 2/1/18 | |||
| 1/19/18 | ||||
| For Period End: | 1/10/18 | |||
| 12/4/17 | ||||
| List all Filings | ||||